Hanmi Pharmaceutical Signs Fabry Drug Licensing Deal With BioMarin Worth Up to $237.5 Million
Hanmi Pharmaceutical signed a licensing deal with BioMarin for a Fabry disease drug, worth up to USD 237.5 million.
Related stories
Autobuses de Leon Offers to Buy Mobico for About £308 Million
A report says Spanish transport company Autobuses de Leon made an offer to buy Mobico Group, valuing the British transport company at about £308 million ($412 million).
H impact | MNA | Oct 30, 2026, 09:44 AM UTC
BASF Surprised by Evonik’s Refusal to Enter Takeover Talks
BASF said it was surprised by Evonik’s unwillingness to enter takeover negotiations.
M impact | MNA | Oct 30, 2026, 09:27 AM UTC
BASF Says Evonik Unwilling to Enter Takeover Negotiations
BASF said it was surprised that Evonik was not prepared to enter takeover negotiations, despite BASF's description of its offer as attractive and its commitments regarding employee
M impact | MNA | Oct 30, 2026, 09:27 AM UTC
Warburg Pincus Announces Public Delisting Offer for PSI
Warburg Pincus announced a public acquisition offer for PSI on Oct. 20, 2026, in connection with a delisting.
M impact | MNA | Oct 30, 2026, 08:52 AM UTC
Evonik Rejects BASF Takeover Approach and Declines Negotiations
Evonik Industries said it will not enter takeover negotiations with BASF after reviewing a letter from the rival chemical company.
M impact | MNA | Oct 30, 2026, 08:38 AM UTC
Evonik Rejects Talks With BASF on Possible Takeover Offer
Evonik rejected negotiations with BASF regarding a possible takeover offer.
M impact | MNA | Oct 30, 2026, 08:17 AM UTC